Want to see TSE:BU full AI Analyst Report?
Top Page
Burcon Nutrascience
(TSX:BU)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$2.00
▲(17.65% Upside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by very weak financial performance (deep unprofitability, ongoing cash burn, and negative equity with high leverage). The earnings call provides a meaningful offset with strong recent revenue growth, expanding customer adoption, and defined near-term targets, but execution and funding dependence remain key risks. Technicals are mixed and valuation support is limited given losses and no dividend.
Positive Factors
Commercial traction
Strong sequential growth and repeat purchasing indicate that Burcon’s ingredients are progressing beyond evaluation into commercial use. A broader base of active buyers can support more durable revenue as customers expand applications and order volumes.
Negative Factors
Severe unprofitability
Revenue growth has not yet produced operating leverage: costs remain far above sales and losses are still expanding. Sustained negative margins limit internal funding capacity and make the investment case dependent on a successful future scale-up.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction
Strong sequential growth and repeat purchasing indicate that Burcon’s ingredients are progressing beyond evaluation into commercial use. A broader base of active buyers can support more durable revenue as customers expand applications and order volumes.
Read all positive factors
Burcon Nutrascience (BU) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$25.39M
Dividend YieldN/A
Average Volume (3M)6.58K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth556.85%
EPS Growth-11.49%
CountryCA
Employees14
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-1.14
Shares Outstanding12,692,942
10 Day Avg. Volume9,144
30 Day Avg. Volume6,578
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)-4.05
Price to Sales (P/S)10.37
P/FCF Ratio-2.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)C$11.60M
Burcon Nutrascience Business Overview & Revenue Model
Company Description
Burcon NutraScience Corporation, along with its associated entities, is a Canadian enterprise specializing in the development and commercialization of plant-derived proteins and functional ingredients for the food and beverage sectors. Its extensi...
How the Company Makes Money
Burcon’s business model is primarily based on monetizing its plant-protein technology and related intellectual property through commercialization arrangements rather than operating large-scale ingredient manufacturing entirely on its own. The comp...
Burcon Nutrascience Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call was constructive and execution-focused: management reported strong sequential and year-over-year revenue growth (54% QoQ; >3x YoY), growing customer adoption with 40 active buyers and repeat purchases, production scaling across multiple products, and put in place financing (up to $8.1M convertible debentures plus $3M undrawn tranche) to expand capacity and pursue near-term targets. Material risks remain — the company is still unprofitable, depends on additional funding and capacity expansions, and growth is back-end loaded and contingent on converting its sales funnel. On balance, the positives around commercial validation, production progress and committed financing outweigh the risks, although execution and timing remain key.Positive Updates
Strong Revenue Growth
Q1 revenue of $1.3 million, representing 54% quarter-over-quarter growth and a more than threefold increase year-over-year; sequential quarter revenue growth reported every period since Galesburg operations began.
Negative Updates
Ongoing Operating Losses and Small Absolute Scale
Despite a 7% quarterly reduction in operating loss, the company remains unprofitable with relatively modest absolute revenue ($1.3 million) and is still early-stage in scaling recurring revenue to meaningful levels.
Read all updates
Q1-2027 Updates
Positive
Negative
Strong Revenue Growth
Q1 revenue of $1.3 million, representing 54% quarter-over-quarter growth and a more than threefold increase year-over-year; sequential quarter revenue growth reported every period since Galesburg operations began.
Read all positive updates
Company Guidance
Management provided quantified near-term guidance and operating metrics: Q1 fiscal 2027 revenue was $1.3 million (up 54% QoQ and over threefold YoY) with operating loss down ~7% QoQ; the company has 40 active buying customers, has launched sunflower, Peazazz C, FavaPro and Puratein products, and cites a market opportunity of roughly $17–$20 million in incremental protein growth. To fund capacity and growth investments it announced an up-to‑$8.1 million convertible debenture offering (48‑month term) with significant insider participation, expects close in late September/early October after the Sept. 16 shareholder meeting, and retains $3.0 million undrawn on tranche 2 of its senior secured loan; management expects double‑digit revenue by year‑end and to cross over to cash‑flow positive in the calendar year as production capacity is expanded.Burcon Nutrascience Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.20M | 2.26M | 381.40K | 184.36K | 363.91K | 171.47K |
| Gross Profit | -9.51M | -8.02M | -870.76K | 184.36K | 363.91K | 171.47K |
| EBITDA | -9.25M | -8.72M | -7.43M | -6.23M | -18.90M | -9.92M |
| Net Income | -14.54M | -14.25M | -8.26M | -7.45M | -25.36M | -10.26M |
Balance Sheet | ||||||
| Total Assets | 23.21M | 22.99M | 30.66M | 12.91M | 9.90M | 29.35M |
| Cash, Cash Equivalents and Short-Term Investments | 866.46K | 950.53K | 7.28M | 4.20M | 1.46M | 7.00M |
| Total Debt | 28.95M | 24.42M | 22.40M | 6.67M | 5.17M | 73.14K |
| Total Liabilities | 32.27M | 28.79M | 23.71M | 7.76M | 5.76M | 1.10M |
| Stockholders Equity | -9.05M | -5.80M | 6.94M | 5.15M | 4.14M | 28.25M |
Cash Flow | ||||||
| Free Cash Flow | -9.75M | -10.12M | -5.82M | -5.90M | -6.38M | -7.18M |
| Operating Cash Flow | -8.89M | -9.16M | -5.51M | -5.78M | -6.02M | -5.91M |
| Investing Cash Flow | -802.80K | -883.39K | -1.66M | -39.49K | -4.43M | -1.23M |
| Financing Cash Flow | 6.24M | 3.85M | 10.23M | 8.56M | 4.90M | 174.08K |
Burcon Nutrascience Technical Analysis
Negative
1.70
Price Trends
1.96
Negative
2.02
Negative
1.98
Negative
Market Momentum
>-0.01
Negative
47.20
Neutral
58.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BU, the sentiment is Negative. The current price of 1.7 is below the 20-day moving average (MA) of 1.85, below the 50-day MA of 1.96, and below the 200-day MA of 1.98, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.20 is Neutral, neither overbought nor oversold. The STOCH value of 58.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BU.
Burcon Nutrascience Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | C$25.39M | -1.62 | 1249.92% | ― | 556.85% | -11.49% | |
45 Neutral | C$31.53M | -20.35 | 47.73% | ― | 32.91% | 55.73% | |
41 Neutral | C$715.25K | -0.17 | -345.48% | ― | 3288.96% | 50.66% |
* Consumer Defensive Sector Average
TSE:BU
Burcon Nutrascience
1.85
-0.84
-31.23%
TSE:DTEA
DAVIDsTEA
0.92
-0.10
-9.80%
TSE:NPRA
Nepra Foods
0.23
0.14
142.11%
TSE:CULT
Cult Food Science Corp.
0.29
-0.21
-42.00%
Burcon Nutrascience Corporate Events
Business Operations and StrategyFinancial Disclosures
Burcon Sets August 12 Call to Review Fiscal 2027 Q1 Results
Neutral
Aug 7, 2026
Burcon NutraScience will host an investor conference call and webcast on August 12, 2026, at 5:00 p.m. Eastern time to discuss its fiscal 2027 first-quarter financial results, which will be released earlier that day. The event, accessible via the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.